Skip to main content
Equibles
NMTC logo

NMTC · NEUROONE MEDICAL TECHNOLOGIES Corp · Webcasts, Transcripts & Audio

Track NMTC — free

Use NMTC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NMTC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.97 +0.11 (+12.96%) At close · Oct 29 Q3 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$7.82M
Shares
9.11M
Volume · Oct 29 66.81K Avg daily vol (3M) 342.04K

NEUROONE MEDICAL TECHNOLOGIES Corp Webcasts

Earnings calls, investor updates, investor days and conferences for NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Conference
Investor event
2026-09-09
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) September 9, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-08-13
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q3 2026 Earnings Call Transcript
Positive tone Revenue growth and order backlog Manufacturing capacity constraints and supply chain International expansion via ISO 13485 certification
Revenue
$1.97M
▲ 16.3% YoY
Diluted EPS
$-0.28
Gross margin
59.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-05-12
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q2 2026 Earnings Call Transcript
Confident tone Trigeminal Nerve Ablation System International Expansion / ISO 13485 1RF Brain Ablation Revenue Growth
Revenue
$1.86M
▲ 34.3% YoY
Diluted EPS
$-0.28
Gross margin
53.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-17
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) March 17, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-02-17
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q1 2026 Earnings Call Transcript
Confident tone 1RF brain ablation system adoption Fiscal 2026 revenue guidance Strategic partnership / licensing discussions
Revenue
$2.89M
▼ 11.7% YoY
Diluted EPS
$-0.18
▼ 150% YoY
Gross margin
54.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2025-12-17
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q4 2025 Earnings Call Transcript
Confident tone OneRF Brain Ablation Commercialization with Zimmer Biomet Spinal Cord Stimulation / Pain Management Financial Performance FY2025
Revenue
$2.74M*
▲ 906.6% YoY
Gross margin
55.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-08-14
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q3 2025 Earnings Call Transcript
Confident tone OneRF ablation system and patient outcomes Revenue growth and guidance Intellectual property and regulatory
Revenue
$1.70M
▲ 105.4% YoY
Diluted EPS
$-0.19
Gross margin
53.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-05-13
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q2 2025 Earnings Call Transcript
Confident tone OneRF Ablation System Commercial Traction Revenue Growth and FY2025 Guidance Trigeminal Nerve Ablation 510(k) Submission
Revenue
$1.39M
▲ 0.7% YoY
Diluted EPS
$-0.44
Gross margin
55.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-02-12
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q1 2025 Earnings Call Transcript
Confident tone OneRF Ablation System Commercialization & Clinical Results Revenue & Gross Margin Growth Zimmer Biomet Partnership
Revenue
$3.27M
▲ 234.9% YoY
Diluted EPS
$0.36
Gross margin
58.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-12-17
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q4 2024 Earnings Call Transcript
Confident tone OneRF Ablation System commercial launch Zimmer Biomet partnership expansion Fiscal 2025 financial guidance
Revenue
$272,284*
▼ 63.3% YoY
Gross margin
51.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-08-14
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q3 2024 Earnings Call Transcript
Confident tone Revenue and Operating Results OneRF Ablation System Commercial Launch Capital and Balance Sheet
Revenue
$825,776
▲ 31.1% YoY
Diluted EPS
$-0.60
Gross margin
34.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-05-14
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q2 2024 Earnings Call Transcript
Confident tone Revenue and operating results Evo sEEG commercialization with Zimmer Biomet Liquidity and capital position
Revenue
$1.38M
▲ 195.4% YoY
Diluted EPS
$-0.66
Gross margin
28.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-02-13
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q1 2024 Earnings Call Transcript
Positive tone CEO Absence and Operational Continuity OneRF Ablation System FDA Clearance and Launch OneRF Pain Applications
Revenue
$977,649
▲ 753.3% YoY
Diluted EPS
$-0.84
Gross margin
27.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q3
2023-08-14
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q3 2023 Earnings Call Transcript
Revenue
$629,906
▲ 1865.4% YoY
Diluted EPS
$-1.20
Gross margin
38.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-05-11
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q2 2023 Earnings Call Transcript
Revenue
$466,176
▲ 1174.3% YoY
Diluted EPS
$-1.26
Gross margin
6.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-02-14
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q1 2023 Earnings Call Transcript
Revenue
$114,579
▲ 239.5% YoY
Diluted EPS
$-0.66
Gross margin
-10.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-22
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q4 2022 Earnings Call Transcript
Revenue
$68,788*
▲ 42.3% YoY
Gross margin
-21.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-08-11
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q3 2022 Earnings Call Transcript
Revenue
$32,049
▼ 20.1% YoY
Diluted EPS
$-1.02
Gross margin
-20.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-05-12
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q2 2022 Earnings Call Transcript
Revenue
$36,584
▲ 100.6% YoY
Diluted EPS
$-1.14
Gross margin
-99.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-02-14
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q1 2022 Earnings Call Transcript
Revenue
$33,748
▼ 52.8% YoY
Diluted EPS
$-1.08
Gross margin
-38.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-15
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q4 2021 Earnings Call Transcript
Revenue
$48,336*
Gross margin
-35.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-08-13
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q3 2021 Earnings Call Transcript
Revenue
$40,096
Diluted EPS
$-1.50
Gross margin
-54.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–22 of 22 webcasts
Key facts CIK 1500198 CUSIP 64130M308 13F (30d) 3 filings 3 filers Visit website Investor relations